At Meiji Seika Pharma, the R&D structure of the pharmaceuticals business is composed of the Pharmaceuticals Research Center, the CMC Research Laboratory, the Bioscience Laboratory, and the Agricultural & Veterinary Research Laboratory. These laboratories conduct a wide range of R&D activities with the objective of becoming a speciality pharmaceutical company in the field of infectious diseases and CNS disorders, and also focus on generic drugs, agricultural chemicals, and veterinary drugs.
We believe a key strategy for strengthening the bases for these operations is to increase the number of product candidates in the product pipeline.
Regarding research and development of ethical pharmaceuticals, we are taking a short-, medium- and long-term perspective as we construct an R&D portfolio with diversified risk that includes in-house drug discovery research and encompasses product lifecycle management (including development of broader indications, new uses, administration methods, and drug formulations) and the development of in-licensing products.
As a new approach in our core area of drugs for infectious diseases and disorders, we are adopting a long-term view in our research of antibody pharmaceuticals and biotechnology-based drugs.
To realize these objectives, we have established a system that centrally promotes the R&D portfolio, resource management, and alliances (sales tie-ups, the development of partnerships for in-licensing products, collaborative research, and out-licensing), and have created an organizational structure to fortify drug discovery research and lifecycle management development.
We are also aiming to realize sustained growth as a “Speciality and Generic Pharmaceuticals Company” with an eye toward the global development of our in-house drug discovery products to create an overseas development structure and cultivate opportunities for finding partners for product launches in overseas markets. To this end, for example, we have taken steps such as setting up representative offices in the United States.
List of New Products Under Development
As of May 2012
| Stage | Name | Type | Efficacy Classification | Notes |
|---|---|---|---|---|
| NDA | MEIACT MS® FINE GRANULES 10% (Cefditoren pivoxil) |
Oral | Antibiotic | In-house (New Dosage) |
| ME2080 (Stiripentol) | Oral | Antiepileptic | In-license:Biocodex (France) | |
| PII | REFLEX® (Mirtazapine) |
Oral | Fibromyalgia treatment (Additional indications) |
In-license:MSD K.K .(formerly, Nippon Organon K.K.) |
| ME2112 (Ziprasidone) |
Oral | Antipsychotic | In-license:RaQualia Pharma Inc. | |
| PI | ME1071 | Injection | Metallo-β-lactamase inhibitor | In-house |
| ME3113 (Udenafil) | Oral | Benign prostatic hyperplasia treatment | In-license:Dong-A Pharmaceutical Co.,Ltd. (Korea) | |
| PI Overseas |
AM-831 | Oral | Antipsychotic | In-license:ACADIA Pharmaceuticals (USA) |
